Centessa Pharmaceuticals PLC ADR (NASDAQ:CNTA) — Market Cap & Net Worth
Market Cap & Net Worth: Centessa Pharmaceuticals PLC ADR (CNTA)
Centessa Pharmaceuticals PLC ADR (NASDAQ:CNTA) has a market capitalization of $6.10 Billion ($6.10 Billion) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3204 globally and #1120 in its home market, demonstrating a -0.45% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Centessa Pharmaceuticals PLC ADR's stock price $39.43 by its total outstanding shares 154662092 (154.66 Million). Review CNTA current and long-term liabilities to assess the company's total debt and financial obligations.
Centessa Pharmaceuticals PLC ADR Market Cap History: 2021 to 2026
Centessa Pharmaceuticals PLC ADR's market capitalization history from 2021 to 2026. Data shows growth from $1.74 Billion to $6.15 Billion (12.89% CAGR).
Index Memberships
Centessa Pharmaceuticals PLC ADR is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.25% | #70 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.01% | #347 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.36% | #46 of 263 |
Weight: Centessa Pharmaceuticals PLC ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Centessa Pharmaceuticals PLC ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Centessa Pharmaceuticals PLC ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
257.87x
Centessa Pharmaceuticals PLC ADR's market cap is 257.87 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $1.23 Billion | $6.85 Million | -$151.09 Million | 179.65x | N/A |
| 2025 | $3.87 Billion | $15.00 Million | -$197.53 Million | 257.87x | N/A |
Competitor Companies of CNTA by Market Capitalization
Companies near Centessa Pharmaceuticals PLC ADR in the global market cap rankings as of June 17, 2026.
Key companies related to Centessa Pharmaceuticals PLC ADR by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Centessa Pharmaceuticals PLC ADR Historical Marketcap From 2021 to 2026
Between 2021 and today, Centessa Pharmaceuticals PLC ADR's market cap moved from $1.74 Billion to $ 6.15 Billion, with a yearly change of 12.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $6.15 Billion | +58.94% |
| 2025 | $3.87 Billion | +49.31% |
| 2024 | $2.59 Billion | +110.43% |
| 2023 | $1.23 Billion | +156.77% |
| 2022 | $479.45 Million | -72.47% |
| 2021 | $1.74 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of Centessa Pharmaceuticals PLC ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.10 Billion USD |
| MoneyControl | $6.10 Billion USD |
| MarketWatch | $6.10 Billion USD |
| marketcap.company | $6.10 Billion USD |
| Reuters | $6.10 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Centessa Pharmaceuticals PLC ADR
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as we… Read more